Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT
Sung Won Choi(University of Michigan), Pavan Reddy(Wichita State University), Charles A. Dinarello(University of Colorado Anschutz Medical Campus), Mary Riwes(University of Michigan), Erin Gatza(Pediatrics and Genetics), Israel Henig(Rush University Medical Center), Brian Parkin(AdventHealth Orlando), Thomas Braun(University of Michigan), John Magenau(University of Michigan), Greg Yanik(Michigan Medicine), Attaphol Pawarode(University of Michigan)
Cited by 68
Related Papers
Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome
|Critical Care Medicine|2015|858
Differential requirement for the activation of the inflammasome for processing and release of IL-1β in monocytes and macrophages
|Blood|2008|777
Gut microbiome–derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease
|Nature Immunology|2016|727
OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation
|Proceedings of the National Academy of Sciences|2018|556